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g.2012.0Abstract Optimization of interferon-based treatment regimens remains an important goal as pegy-
lated interferon is likely to remain the backbone of chronic HCV treatment in the foreseeable future.
The objective of the current study was to evaluate virological response at week 8 of combined treat-
ment as a predictor of sustained virologic response (SVR) in non rapid virologic response (RVR),
chronic HCV genotype 4 infected patients.
A total of 38 patients with chronic HCV genotype 4 infection were enrolled in the study. All
patients received a combination of pegylated interferon a-2a plus ribavirin. Virological response at
week 8 of combined treatment was evaluated as a predictor of SVR.
Week 8 response was more sensitive but less speciﬁc than RVR in predicting SVR, in non RVR patients
(24 patients), week 8 response had a sensitivity of 45.5% and a speciﬁcity of 76.9% for predicting SVR.
In conclusion: In non RVR patients, measurement of HCV RNA at week 8 is an optimal time to iden-
tify those who are not going to beneﬁt from pegylated interferon and ribavirin combination therapy.
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HCV genotype 4 (HCV-4) is common in the Middle East and
in Africa, where it is responsible for more than 80% of HCV
infections, and has recently spread to several European coun-
tries [1]. Egypt has the highest prevalence of HCV worldwide
(15%) [2] and the highest prevalence of HCV-4, which is
responsible for almost 90% of infections and is considered a
major cause of chronic hepatitis, liver cirrhosis, hepatocellular
carcinoma, and liver transplantation in the country [3].
The combination of pegylated interferon plus ribavirin is
the treatment of choice for patients with chronic hepatitis
C [4]. Optimization of interferon-based treatment regimens
remains an important goal as pegylated interferon is likely
to remain the backbone of treatment in the foreseeable
future.
The rate and extent of virologic response to combination
therapy in patients infected with hepatitis C virus (HCV) geno-
type 1 or 4 is highly variable [5,6]. In patients with chronic hep-
atitis C, the on-treatment response at weeks 4 and 12 of
pegylated interferon plus ribavirin combination therapy may
be used to predict the probability of sustained virologic re-
sponse (SVR). Patients achieving rapid virologic response
(RVR) (HCV RNA <50 IU/mL at week 4) have a high rate
of SVR, irrespective of HCV genotype [7].
The standard deﬁnition of an early virologic response
(EVR) is undetectable HCV RNA (<50 IU/mL) by qualitative
PCR or aP2 log drop in HCV RNA at week 12 by quantita-
tive PCR [6]. However, the positive predictive value of an EVR
is not high enough to be a useful clinical predictor of SVR [8].
To our knowledge, the value of virological response at week
8 of combined treatment as a predictor of SVR in non RVR
chronic HCV genotype 4 infected patients has not been well
evaluated.
The objective of the current study was to evaluate virolog-
ical response at week 8 of combined treatment as a predictor of
SVR in non RVR chronic HCV genotype 4 infected patients.
2. Patients and methods
A total of 38 treatment naı¨ve patients with chronic HCV geno-
type 4 infection were enrolled in the study (36 males and 2 fe-
males with ages ranging from 32 to 48 years ‘‘mean = 40’’).
All patients were fulﬁlling the criteria for combined treat-
ment with pegylated interferon a-2a and ribavirin.
All patients were subjected to the following:
 History taking, thorough clinical examination including
fundus examination, laboratory investigations including:
fasting and post prandial blood glucose level, liver function
tests, Alpha-fetoprotein, prothrombin time and INR, renal
function tests, serum ceruloplasmin, complete blood count,
free T3, free T4, TSH (Thyroid Stimulating Hormone),
ANA (Antinuclear Antibody), HIV (Human Immune Deﬁ-
ciency Virus) antibody and hepatitis C virus antibody using
ELISA (Enzyme Linked Immune Sorbant Assay)
technique.
 Hepatitis B Virus (HBV) markers (HBsAg, HBsAb,
HBcAb, HBeAg and HBeAb).
 HCV RNA in serum, both quantitative and qualitative
using Polymerase Chain Reaction (PCR): Automated PCR (using Cobas Ammplicor HCVv2.0,
Roche molecular system) was used for qualitative HCV
RNA detection.
 Manual PCR (using Cobas Ammplicor HCVv2.0, Roche
molecular system) was used for quantifying HCV RNA.
 Interpretation of viremia:
<200.000 IU/ml: low viremia.200.000–2000.000 IU/ml: moderate viremia.
>2000.000 IU/ml: high viremia.
 HCV genotyping using INNO-LIPA HCVII test (INNO-
LiPA HCV II, Innogenetics, Ghent, Belgium), this test is
based on reverse hybridization of 50 untranslated region
PCR ampliﬁcation product [9].
 Abdominal ultrasonography (Aloka SSD620, Japan) using
3.5 MHz convex probe.
 Fibroscan was done for all patients. Fibroscan is designed
for non invasive assessment of liver ﬁbrosis and is based
on elastometry (or one dimensional transient elastography),
the harder the tissue, the faster the shear wave propagates
[10].
 The tip of the transducer probe was placed on the skin,
between the ribs, at the level of the right lobe. Once the tar-
get area has been located, acquisition was triggered by
pressing a button. The measurement depth is between 25
and 65 mm below the skin surface. In this study, at least
5 successful measurements were made in each patient. The
median value of all successful acquisitions in each patient
was recorded as the liver elastic modulus. The operator
who performed the liver stiffness measurement was una-
ware of neither the clinical nor the laboratory data of the
patients. Results are expressed in kilopascal (kPa).
 The values used to correlate elastometry with METAVIR
scoring system are the followings: <7.1 kPa for F0–1,
7.1–9.4 kPa for F2, 9.5–12.5 kPa for F3 and >12.5 kPa
for F4 [11].
 All patients received a combination of pegylated interferon
a-2a 180ucg SC injection weekly plus ribavirin 800–
1200 mg/day (dose adjusted according to body weight).
 This study was approved by the local ethical committee of
the Ain Shams University hospitals and a written consent
was obtained from each individual before participation in
the study.
Exclusion criteria:
1. Patients with decompensated cirrhosis.
2. Patients with hepatocellular carcinoma.
3. Patients with diabetes mellitus.
4. Patients with HBV infection.
5. Current pregnancy or breastfeeding.
6. Prior or current anti viral therapies.
7. Regular or excessive alcohol consumption.
8. Other liver diseases as alcoholic liver disease, non alco-
holic fatty liver disease (NAFLD), drug-induced hepati-
tis, other viral hepatitis, hereditary haemochromatosis,
Wilson’s disease, autoimmune hepatitis, primary biliary
cirrhosis, primary sclerosing cholangitis and a1 antitryp-
sin deﬁciency.
9. Morbid obesity (BMIP 40).
10. Current intravenous drug abuse.
11. Neutropenia (<1500/mm3).
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13. Serum creatinine more than 1.5 times the upper limit of
normal value.
14. Severe cardiac, pulmonary, retinal, thyroid, or psychiat-
ric disorders.
15. HIV infection.3. Statistical methods
The data were collected, coded and entered to a personal com-
puter (P.C.) IBM compatible 2.6 GHz. The data were analyzed
with the program statistical package for social science (SPSS)
under windows version 11.0.1.
4. Calculation of sensitivity and speciﬁcity
Sensitivity = TP/TP + FN.
Speciﬁcity = TN/TN+ FP.
Positive predictive value (PPV) = TP/TP + FP.
Negative predictive value (NPV) = TN/TN+ FN.
Accuracy = TP+ TN/All cases.
TN = true negative.
TP = true positive.
FN = false negative.
FP = false positive.
5. Results
A total of 38 patients with chronic HCV genotype 4 infection
were enrolled in the study (36 males and 2 females with ages
ranging from 32 to 48 ‘‘mean = 40’’).
All patients had pretreatment moderate viremia with HCV
RNA ranging from 200.000 to 2000.000 IU/ml.Table 1 Comparison between RVR and SVR.
RVR SVR
Responders N= 21
No.
Responders N= 14 10 (TP)
Non responders N= 24 11 (FN)
SVR: sustained virologic response.
RVR: rapid virologic response.
TN= true negative, TP = true positive.
FN= false negative, FP = false positive.
Sensitivity = 47.6%, Speciﬁcity = 76.5%.
Positive predictive value (PPV) = 71.4%, negative predictive value NPV
Accuracy = 60.5%.
Table 2 Comparison between week 8 response and SVR.
Week 8 SVR
Responders N= 21
No.
Responders N= 21 15 (TP)
Non responders N= 17 6 (FN)
Sensitivity = 71.4%, speciﬁcity = 64.7%.
PPV= 71.4%, NPV= 64.7%.
Accuracy = 68.4%.Twenty-one patients had a pretreatment ﬁbroscan score
ranging from 7.1 to 9.4 kPa (F2) and the remaining 17 patients
had a pretreatment ﬁbroscan score ranging from 9.5 to
12.5 kPa (F3).
All patients received a combination of pegylated interferon
a-2a plus ribavirin.
Virological response at week 8 of combined treatment was
evaluated as a predictor of SVR (response after 24 weeks of
discontinuation of treatment) in thepatients who failed to
achieve RVR (week 4 response).
Of the 38 patients, 14 (36.8%) patients achieved RVR and
21 patients (55.2%) achieved SVR (Table 1).
10 out of 14 RVR patients achieved SVR (71.4% of RVR
patients) and 11 out of 24 non RVR patients achieved SVR
(45.8% of non RVR patients) (Table 1).
Of the RVR patients, 13 out of 14 patients had an undetect-
able HCV RNA at week 8 of therapy and of these 13 patients,
only 10 patients achieved SVR.
Twenty-four patients failed to achieve RVR. Only 8 of
these patients (33.3% of non RVR patients) had an undetect-
able HCV RNA at week 8 of therapy and of these 8 patients,
only 5 patients (62.8% of non RVR patients who had an unde-
tectable HCV RNA at week 8 of therapy) achieved SVR (Ta-
ble 3).
Sixteen non RVR patients (66.6% of non RVR patients)
had detectable HCV RNA at week 8 of therapy and only 6
out of these 16 patients (37.5% of non RVR patients who
had detectable HCV RNA at week 8 of therapy) achieved
SVR (Table 3).
Regarding EVR in non RVR patients, only 14 patients
(58.3% of non RVR patients) achieved EVR and of these, only
9 patients (62.5% of non RVR patients who achieved EVR)
achieved SVR. Among the 10 patients who failed to achieveNon response N= 17
% No. %
47.6 4 (FP) 23.5
45.8 13 (TN) 76.5
= 54.2%.
Non responders N= 17
% No. %
71.4 6 (FP) 35.3
28.6 11 (TN) 64.7
Table 3 Comparison between week 8 response and SVR among non RVR patients.
Week8 SVR
Responders N= 11 Non responders N= 13
No. % No. %
Responders N= 8 5 (TP) 45.5 3 (FP) 23.1
Non responders N= 16 6 (FN) 54.5 10 (TN) 76.9
Sensitivity = 45.5%, speciﬁcity = 76.9%.
PPV= 62.5%, NPV= 62.5%.
Accuracy = 62.5%.
Table 4 Comparison between EVR and SVR among non RVR patients.
EVR SVR
Responders N= 11 Non responders N= 13
No. % No. %
Responders N= 14 9 (TP) 65.2 5 (FP) 35.7
Non responders N= 10 2 (FN) 20.0 8 (TN) 80.0
EVR: early virologic response.
Sensitivity = 81%, speciﬁcity = 61.5%.
PPV= 64.2%, NPV= 80.0%.
Accuracy = 70.8%.
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non RVR patients who failed to achieve EVR) achieved SVR
(Table 4).
Week 8 response was more sensitive (71.4% vs. 47.6%) but
less speciﬁc (64.7 vs. 76.5%) than RVR in predicting SVR
(Tables 1 and 2).
Both RVR and week 8 responses had the same PPV
(71.4%) but the NPV of week 8 response was higher than that
of RVR (64.7% vs. 54.2%) (Tables 1 and 2).
In non RVR patients, week 8 response was less sensitive
(45.5% vs. 81%) but more speciﬁc (76.9% vs. 61.5%) than
EVR in predicting SVR (Tables 3 and 4).
The positive and negative predictive values of week 8 re-
sponse were lower than the predictive values of EVR (62.5%
vs. 64.2% and 62.5% vs. 80%, respectively) (Tables 3 and 4).
6. Discussion
The management strategies for patients infected with HCV-
4 are not yet well established. The limited distribution of
this genotype in the Western countries and subsequently
the small percentage of HCV-4 patients in major multicen-
ter HCV therapeutic trials may in part explain this phe-
nomenon [12].
The response to antiviral therapy in HCV-infected patients
is heterogeneous and, despite increases in SVR rates, treatment
outcomes with peg-interferon a-2a plus ribavirin are not opti-
mal in certain patient populations and might still be improved
[13,14].
While some authors found that both RVR and complete
early virologic response are associated with the achievement
of SVR in patients with (chronic hepatitis C) CHC, others
found the positive predictive value of an EVR not high enough
to be a useful clinical predictor of SVR [8].Early identiﬁcation of those patients who are unlikely to
achieve SVR may help to reduce unnecessary healthcare ex-
penses and limit the side-effects associated with drug
exposure.
The objective of the current study was to evaluate virolog-
ical response at week 8 of combined treatment as a predictor of
SVR in non RVR chronic HCV genotype 4 infected patients.
In the current study, 36.8% of patients achieved RVR and
55.2% achieved SVR. This result goes in agreement with a ret-
rospective analysis of SVR rates which was done among 205
naive French and Egyptian HCV-4 patients and revealed a bet-
ter overall SVR in Egyptians than in Europeans (54.9% vs.
40.3%) treated with PEG-IFN and ribavirin [15].
In RVR patients, SVR was 71%. In contrast, only 45.8% of
non RVR patients achieved SVR. These results conﬁrm other
reports which found SVR rates to be highest among patients
who achieve RVR [16,17].
Regarding EVR in non RVR patients, only 58.3% of pa-
tients achieved EVR and of these, 62.5% achieved SVR.
41.6% of patients failed to achieve EVR and 20.0% of these
patients achieved SVR.
In comparison EVR rate that was found in the present
study with EVR rate reported by Ferenci and co-workers
[18], a higher EVR was observed.
The fact that EVR was evaluated only in non RVR patients
may in part explain this higher rate. Also differences in the eth-
nicity, number of patients included in each study, viral geno-
type and/or subtype and baseline viral load make any direct
comparison with the present study difﬁcult.
In non RVR patients, only 33.3% of patients had an unde-
tectable HCV RNA at week 8 of treatment and 62.5% of these
patients achieved SVR. 66.6% non RVR patients had detect-
able HCV RNA at week 8 of therapy and of these patients,
only 37.5% achieved SVR.
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and EVR encouraged incorporation of on-treatment virologi-
cal response at week 8 into the treatment algorithm for pa-
tients with genotype 4 infection who fails to achieve RVR to
provide clinicians with a useful tool to identify patients who
are unlikely to achieve SVR.
In accordance with this conclusion, the present study found
that week 8 response was more speciﬁc (76.9% vs. 61.5%) than
EVR in predicting SVR. This result also highlights the value of
week 8 response in identifying patients who are less likely to
achieve SVR.
Despite the relatively high speciﬁcity of week 8 response for
the prediction of SVR in non RVR patients, the NPV of this
test was lower than the NPV of EVR that was reported not
only by the present study but also by other reports [19,20].
The NPV for week 8 response reported by the current study
was measured only for non RVR patients. In contrast, the
NPV of EVR reported by other studies was measured for all
patients irrespective of week 4 response.
This study was limited by the relatively small sample size,
reducing the statistical power to evaluate virological response
at week 8 of combined treatment as a predictor of SVR in
non RVR chronic HCV genotype 4 infected patients. How-
ever, the result of the study encourages the conduction of fur-
ther studies on a larger scale of patients.
7. Conclusion
In non RVR patients, measurement of HCV RNA at week 8 is
an optimal time to identify those who are unlikely to beneﬁt
from pegylated interferon and ribavirin combination therapy.
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